The Psychopath Test shows how powerful industries cultivate and reward certain forms of “madness” via Ronson’s explorations of individuals in positions of economic, social, or political power. Ronson draws lines between media practices, psychiatric expansion, pharmaceutical marketing, and corporate culture to reveal a system that profits when extreme behavior appears in public view. This network of societal powers encourages forms of pathology that fit its needs, and the result is a culture where the boundary between genuine illness and manufactured disorder becomes faint.

Ronson incorporates interviews with top officials and public figures to reinforce his theory about the unethical incentives for generating or exploiting mental illness. For example, Ronson’s conversation with Charlotte Scott, a former daytime television guest booker, explains how the media shapes these incentives. Scott describes looking for guests who are “just mad enough” (175) to entertain viewers and says she checks medication lists to find candidates who might offer the ideal amount of drama for her show: A person on Prozac would fit her criteria because that person is “depressed enough to go to a doctor” (175) while still able to perform on camera. Her method turns private distress into a product for broadcast. Ronson uses the case of former MI5 agent David Shayler to show the same pattern from another angle. When Shayler claims that holographic planes appeared on 9/11, television execs treat his theory as ideal for their shows—demonstrating his conspiracy theory as both compelling, outrageous, and entertaining without being overtly harmful. Later, when he declares that he is the Messiah, the media loses interest. The shift in how the media treats and portrays David reveals a system that highlights forms of instability that make good television and ignores the rest. This dynamic augments stigmas around mental illness and fails to create real public awareness.

To deepen his explorations, Ronson delves into the psychiatric and pharmaceutical incentives that encourage diagnostic growth. Robert Spitzer’s DSM‑III expands the list of mental disorders, turning a short manual into a full catalog of abnormalities. Allen Frances, an editor of a later edition, acknowledges that this expansion contributed to “false epidemics” (243) such as childhood bipolar disorder. Pharmaceutical companies used these new categories to reach more patients, and their marketing helped shape public understanding of mental illness. While corporations benefited, innocent lives were endangered. Ronson underscores the death of four‑year‑old Rebecca Riley from an overdose of bipolar medication prescribed to her at age three as a painful example of what can happen when diagnostic growth and commercial pressures meet.

Ronson’s discussion of corporate behavior rounds out his argument, connecting private and public concerns regarding manufacturing mental illness. CEO Al Dunlap, known as “Chainsaw Al,” built a reputation for harsh downsizing in his companies. Investors praised this approach, and when he was hired at Sunbeam, the company’s stock rose sharply. Reports from that period describe his “Draconian cuts” (168) as strengths, illustrating how the corporate world can reward traits that resemble Hare’s checklist’s description of psychopathy. Within this context, behavioral features that register as pathological in clinical settings are celebrated as leadership qualities. Ronson’s account reveals a landscape where several industries encourage extreme behavior, label it, and use it to push their interests. Mental illness, he suggests, isn’t a fixed concept. The same traits that might condemn a person—or subject them to public mockery—might also foster a different person’s rise to social prominence.